Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

US FDA's New Neurology Leadership Likely To Face Two Big Reviews In 2020

Nov 25 2019

• By Ramsey Baghdadi

brain, thinking concept; 3d illustration - Illustration

Related Content

ODE-1 Director Unger, Not Medical Officer, Conducted Epidiolex Safety Review

Sep 26 2018

Keeping Track: Scenesse, Reyvow, and Beovu Make Trio Of Novel Approvals

Oct 13 2019

Biogen Aducanumab BLA Plan Is In Line With US FDA Neurology Division Precedent

Nov 11 2019

Drug Review Reorganization At US FDA Coming Into Focus

Nov 07 2019

Sarepta Tells Patients To Stand Down, Golodirsen Future 'Our Responsibility'

Aug 28 2019

Related Companies

Biogen, Inc.

Sarepta Therapeutics, Inc.

GW Pharmaceuticals plc

Eli Lilly and Company

Additional Topics

United States Drug Approval Standards Leadership Drug Review FDA Regulation Neurology BioPharmaceutical

More from Approval Standards

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window